SRT1720 CAS:1001645-58-4

CAS NO: 1001645-58-4
SRT1720 CAS:1001645-58-4
Description Review
Description

SRT-1720 HCl (SRT1720 HCl) (CAS: 1001645-58-4) is a small molecule that acts as an activator of sirtuin 1 (SIRT1), a protein involved in the regulation of various cellular processes such as metabolism, inflammation, and aging. It has been investigated as a potential therapeutic agent for several age-related diseases, including metabolic disorders and cancer.

Chemical name: (2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl)-N-(quinoxalin-6-yl)acetamide hydrochloride

Molecular formula: C22H23N7O.S.ClH

Formula weight: 490.99 g/mol

CAS No: 1001645-58-4

Top ten keywords from Google:

  1. SRT-1720 clinical trials
  2. SIRT1 activator
  3. Metabolic disorders
  4. Cas: 1001645-58-4
  5. Anti-aging
  6. Cancer research
  7. Inflammation
  8. Cellular metabolism
  9. Oxidative stress
  10. Neurodegenerative diseases

Synonyms:

  • SRT1720 HCl
  • CAS: 1001645-58-4

Health benefits of this product: SRT-1720 HCl has demonstrated potential health benefits in the area of anti-aging and the treatment of several age-related diseases, including metabolic disorders, cancer, and neurodegenerative diseases. Its primary mode of action is through the activation of SIRT1, leading to improved cellular metabolism, reduced inflammation, and increased antioxidant capacity.

Potential effects: SRT-1720 HCl has demonstrated efficacy in several preclinical studies in improving glucose metabolism, reducing inflammation, and increasing lifespan in animal models. It also has potential benefits for preventing the development of cancer and reducing oxidative stress, which is a key contributor to age-related diseases. SRT-1720 HCl works by activating SIRT1, leading to improved cellular metabolism, reduced inflammation, and increased antioxidant capacity.

Product mechanism: SRT-1720 HCl works by activating SIRT1, a protein involved in the regulation of various cellular processes such as metabolism, inflammation, and aging. SIRT1 is activated by nicotinamide adenine dinucleotide (NAD+), a coenzyme that is involved in energy metabolism. By activating SIRT1, SRT-1720 HCl can improve cellular metabolism, reduce inflammation, and increase antioxidant capacity, leading to improved health outcomes.

Safety: SRT-1720 HCl has been evaluated in several preclinical studies and has been generally well-tolerated. Its safety profile in humans is not well-established, although it has been extensively studied in animal models. Potential side effects may include gastrointestinal symptoms such as nausea, vomiting, and diarrhea.

Side effects: Common side effects of SRT-1720 HCl are not well-established due to its limited use in humans. However, in preclinical studies, potential side effects may include renal and hepatic toxicity, alterations in cardiovascular function, and allergic reactions. Patients should be monitored closely for these adverse events and receive appropriate medical intervention if necessary.

Dosing information: The optimal dose and dosing regimen of SRT-1720 HCl may vary depending on the patient's condition and treatment goals. In preclinical studies, doses ranging from 10 to 100 mg/kg have been evaluated for metabolic disorders and other age-related diseases. Patients should follow their doctor's instructions regarding dosing, administration, and monitoring.

Conclusion: SRT-1720 HCl (SRT1720 HCl) (CAS: 1001645-58-4) is a small molecule that acts as an activator of SIRT1, a protein involved in the regulation of various cellular processes such as metabolism, inflammation, and aging. It has been investigated as a potential therapeutic agent for several age-related diseases, including metabolic disorders and cancer. Although its safety profile in humans is not well-established, it has shown promising results in preclinical studies. Researchers should follow established protocols and guidelines regarding dosing, administration, and monitoring

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code